Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD

Nephrology Dialysis Transplantation

Volumn 27, Issue 6, 2012, Pages 2198-2205

  Miller, Gerald ^a   Davis, James ^a   Shatzen, Edward ^a   Colloton, Matthew ^a   Martin, David ^a   Henley, Charles M ^a  

^a AMGEN INC   (United States)

Author keywords

Calcimimetics; Cinacalcet; Parathyroid hormone; Parathyroid hyperplasia; Secondary hyperparathyroidism

Indexed keywords

BETA CYCLODEXTRIN SULFOBUTYL ETHER; CALCIUM; CALCIUM SENSING RECEPTOR; CINACALCET; CYCLIN DEPENDENT KINASE INHIBITOR 1; PARATHYROID HORMONE; PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM BLOOD LEVEL; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; NONHUMAN; ORGAN SIZE; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PARATHYROID SIZE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RODENT; SECONDARY HYPERPARATHYROIDISM; UREMIA;

ANIMALS; CALCIUM; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE MODELS, ANIMAL; HYPERPARATHYROIDISM, SECONDARY; HYPERPLASIA; KIDNEY FAILURE, CHRONIC; MALE; NAPHTHALENES; PARATHYROID GLANDS; PARATHYROID HORMONE; PHOSPHORUS; RATS; RATS, SPRAGUE-DAWLEY; UREMIA;

EID: 84861856711     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr589     Document Type: Article

References (40)

1. Drueke T, Martin D, Rodriguez M. Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant 2007; 22: 1828-1839
2. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 2011; 6: 913-921
3. Drueke TB. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 1995; 48: 259-272
4. Kaczmarek E, Lacka K, Majewski P et al. Selected markers of proliferation and apoptosis in the parathyroid lesions: a spatial visualization and quantification. J Mol Histol 2008; 39: 509-517
5. Niculescu AB 3rd, Chen X, Smeets M et al. Effects of p.21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 1998; 18: 629-643
6. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9: 1149-1163
7. Tokumoto M, Tsuruya K, Fukuda K et al. Reduced p.21, p.27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int 2002; 62: 1196-1207
8. Dusso AS, Pavlopoulos T, Naumovich L et al. p.21WAF1 and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth1. Kidney Int 2001; 59: 855-865
9. Canalejo A, Canalejo R, Rodriguez ME et al. Development of parathyroid gland hyperplasia without uremia: role of dietary calcium and phosphate. Nephrol Dial Transplant 2010; 25: 1087-1097
10. Komaba H, Goto S, Fujii H et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2009; 77: 232-238
11. Galitzer H, Ben-Dov IZ, Silver J et al. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2009; 77: 211-218
12. Li YC, Pirro AE, Amling M et al. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 1997; 94: 9831-9835
13. Meir T, Levi R, Lieben L et al. Deletion of the vitamin D receptor specifically in the parathyroid demonstrates a limited role for the receptor in parathyroid physiology. Am J Physiol Renal Physiol 2009; 297: F1192-F1198
14. Li YC, Amling M, Pirro AE et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 1998; 139: 4391-4396
15. Van Cromphaut SJ, Dewerchin M, Hoenderop JG et al. Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc Natl Acad Sci USA 2001; 98: 13324-13329
16. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008
17. Brown EM, Gamba G, Riccardi D et al. Cloning and characterization of an extracellular Ca(21)-sensing receptor from bovine parathyroid. Nature 1993; 366: 575-580
18. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 2001; 81: 239-297
19. Henley C, Davis J, Miller G et al. The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats. Eur J Pharmacol 2009; 616: 306-313
20. Nemeth EF, Heaton WH, Miller M et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004; 308: 627-635
21. Nemeth EF, Steffey ME, Hammerland LG et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998; 95: 4040-4045
22. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525
23. Colloton M, Shatzen E, Miller G et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005; 67: 467-476
24. Chin J, Miller SC, Wada M et al. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol 2000; 11: 903-911
25. Wada M, Furuya Y, Sakiyama J et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997; 100: 2977-2983
26. Meola M, Petrucci I, Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant 2009; 24: 982-989
27. Terawaki H, Nakano H, Takeguchi F et al. Regression of parathyroid gland swelling by treatment with cinacalcet. Nephrol Dial Transplant 2009; 24: 690-691. author reply 1-2
28. Komaba H, Fukagawa M. Regression of parathyroid hyperplasia by calcimimetics-fact or illusion? Nephrol Dial Transplant 2009; 24: 707-709
29. Komaba H, Nakanishi S, Fujimori A et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010; 5: 2305-2314
30. Miller J, Davis J, Van G et al. Inhibition of parathyroid gland hyperplasia and increased expression of p.21 in the parathyroid are reversed upon discontinuation of cinacalcet HCl treatment (abstract SP045 ERA-EDTA, Glasgow 2006). Nephrol Dial Transplant 2006; 21 (Suppl 4): iv30
31. WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC/DDD). 2010. http://www.whocc.no/atc-ddd-index/? code/H05BX1 (29 April 2011, date last accessed)
32. Charytan C, Coburn JW, Chonchol M et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 2005; 46: 58-67
33. Chattopadhyay N, Mithal A, Brown EM. The calcium-sensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism. Endocr Rev 1996; 17: 289-307
34. Ho C, Conner DA, Pollak MR et al. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet 1995; 11: 389-394
35. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005; 288: F253-F264
36. Gogusev J, Duchambon P, Hory B et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997; 51: 328-336
37. Kifor O, Moore FD Jr, Wang P et al. Reduced immunostaining for the extracellular Ca21-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81: 1598-1606
38. Yano S, Sugimoto T, Tsukamoto T et al. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int 2000; 58: 1980-1986
39. Brown AJ, Ritter CS, Finch JL et al. Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. Kidney Int 1999; 55: 1284-1292
40. Cozzolino M, Brancaccio D, Gallieni M et al. Pathogenesis of parathyroid hyperplasia in renal failure. J Nephrol 2005; 18: 5-8